Management of locally advanced adenocarcinoma of the pancreas

Hematol Oncol Clin North Am. 2002 Feb;16(1):95-103. doi: 10.1016/s0889-8588(01)00009-0.

Abstract

Pancreatic cancer is one of the deadliest malignancies and is fatal in more than 95% of affected individuals. For locally advanced disease, the combination of 5-FU and radiation appears to offer the best chance for delaying disease progression. The introduction of gemcitabine into chemoradiotherapy regimens may provide additional improvements in the management of patients. Preoperative therapy has proved feasible but has not shown improvement in overall survival.

Publication types

  • Review

MeSH terms

  • Adenocarcinoma / pathology
  • Adenocarcinoma / therapy*
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Chemotherapy, Adjuvant
  • Combined Modality Therapy
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / therapeutic use
  • Doxorubicin / therapeutic use
  • Fluorouracil / administration & dosage
  • Fluorouracil / therapeutic use
  • Gemcitabine
  • Humans
  • Mitomycins / administration & dosage
  • Neoplasm Invasiveness
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Paclitaxel / therapeutic use
  • Pancreatectomy
  • Pancreatic Neoplasms / pathology
  • Pancreatic Neoplasms / therapy*
  • Radiation-Sensitizing Agents / therapeutic use
  • Radioisotope Teletherapy
  • Radiotherapy, Adjuvant
  • Randomized Controlled Trials as Topic
  • Retrospective Studies
  • Streptozocin / administration & dosage

Substances

  • Antineoplastic Agents
  • Mitomycins
  • Radiation-Sensitizing Agents
  • Deoxycytidine
  • Streptozocin
  • Doxorubicin
  • Paclitaxel
  • Fluorouracil
  • Gemcitabine

Supplementary concepts

  • FSM protocol